Find Reports

Select Report Type

Reimbursement Review

Displaying 176 - 200 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
atogepant	Qulipta	atogepant	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Migraine, prevention	Reimburse with clinical criteria and/or conditions	Complete	Feb 23, 2022	Jun 14, 2023	SR0724-000
vericiguat	Verquvo	vericiguat	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Heart failure	Reimburse with clinical criteria and/or conditions	Complete	Oct 14, 2022	Jun 14, 2023	SR0758-000
RET fusion-positive non-small ...			Final Report	RET fusion-positive non-small cell lung cancer		Complete		Jun 1, 2023	PH0026-000
Non-Small Cell Lung Cancer (NS...			Final Report	Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations		Complete		Jun 1, 2023	PH0028-000
risankizumab	Skyrizi	risankizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Crohn's disease	Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2022	May 12, 2023	SR0767-000
upadacitinib	Rinvoq	upadacitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 17, 2022	May 11, 2023	SR0759-000
palovarotene	Sohonos	palovarotene	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Fibrodysplasia Ossificans Progressiva	Reimburse with clinical criteria and/or conditions	Complete	Oct 21, 2022	May 11, 2023	SR0761-000
selumetinib	Koselugo	selumetinib	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Neurofibromatosis type 1	Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2022	May 10, 2023	SR0764-000
fostemsavir	Rukobia	fostemsavir	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Human immunodeficiency virus type 1 (HIV-1)	Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2022	May 10, 2023	SR0760-000
Prostate cancer			Final Report	Prostate Cancer		Complete		May 3, 2023	PH0023-000
ciltacabtagene autoleucel	Carvykti	ciltacabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Relapsed or refractory multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Sep 23, 2022	May 1, 2023	PG0302-000
crisantaspase recombinant	Rylaze	crisantaspase recombinant	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Acute lymphoblastic leukemia	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2022	Apr 26, 2023	PC0301-000
mavacamten	Camzyos	mavacamten	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Obstructive hypertrophic cardiomyopathy	Reimburse with clinical criteria and/or conditions	Complete	Sep 22, 2022	Apr 14, 2023	SR0755-000
Large B-Cell Lymphoma			Final Report	Large B-Cell Lymphoma		Completed		Apr 11, 2023	PH0027-000
caplacizumab	Cablivi	caplacizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Acquired thrombotic thrombocytopenic purpura (aTTP)	Do not reimburse	Complete	Jun 7, 2022	Apr 5, 2023	SR0736-000
nivolumab	Opdivo	nivolumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Resectable Non-Small Cell Lung Cancer	Reimburse with clinical criteria and/or conditions	Complete	Sep 13, 2022	Mar 30, 2023	PC0303-000
brexucabtagene autoleucel	Tecartus	brexucabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Acute lymphoblastic leukemia	Reimburse with clinical criteria and/or conditions	Complete	Sep 16, 2022	Mar 29, 2023	PG0304-000
pegcetacoplan	Empaveli	pegcetacoplan	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Paroxysmal nocturnal hemoglobinuria	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2022	Mar 20, 2023	SR0748-000
finerenone	Kerendia	finerenone	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Chronic kidney disease	Reimburse with clinical criteria and/or conditions	Complete	May 20, 2022	Mar 8, 2023	SR0737-000
Hormone receptor (HR) positive...			Final Report	Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer		Complete		Mar 8, 2023	PH0018-000
lutetium vipivotide tetraxetan	Pluvicto	lutetium vipivotide tetraxetan	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Metastatic castration-resistant prostate cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 21, 2022	Mar 3, 2023	PC0297-000
amivantamab	Rybrevant	amivantamab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Apr 21, 2022	Mar 1, 2023	PC0289-000
olaparib	Lynparza	olaparib	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	gBRCAm, HER2-negative high-risk early breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 3, 2022	Mar 1, 2023	PC0299-000
ravulizumab	Ultomiris	ravulizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Atypical hemolytic uremic syndrome	Reimburse with clinical criteria and/or conditions	Complete	Jun 8, 2022	Feb 27, 2023	SR0740-000
berotralstat	Orladeyo	berotralstat	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	hereditary angioedema (HAE)	Reimburse with clinical criteria and/or conditions	Complete	Feb 22, 2022	Feb 17, 2023	SR0723-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 176 - 200 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Liraglutide for Pediatric Patients with Type 2 Diabetes	Liraglutide for Pediatric Patients with Type 2 Diabetes	Jul 26, 2023	Summary with Critical Appraisal	Completed	RC1494-000
Nirsevimab (Beyfortus) for Respiratory Syncytial Virus Prevention in Neonates and Infants	Nirsevimab (Beyfortus) for Respiratory Syncytial Virus Prevention in Neonates a…	Jul 26, 2023	Technology Review	Complete	HC0059-000
Perioperative Normothermia Interventions to Prevent Caesarean Section Surgical Site Infection	Perioperative Normothermia Interventions to Prevent Caesarean Section Surgical Site Infection	Jul 25, 2023	Summary of Abstracts	Completed	RB1673-000
Electrostimulation Devices for Wounds	Electrostimulation Devices for Wounds	Jul 17, 2023	Rapid Review	Completed	RC1489-000
Point-of-Care HIV and Syphilis Screening	Point-of-Care HIV and Syphilis Screening	Jul 13, 2023	Rapid Review	Completed	RC1490-000
Platelet-Rich Plasma Injections for Chronic Tendinopathies in the Lower Extremities	Platelet-Rich Plasma Injections for Chronic Tendinopathies in the Lower Extremities	Jul 10, 2023	Rapid Review	Completed	RC1486-000
Riluzole for Amyotrophic Lateral Sclerosis Treatment	Riluzole for Amyotrophic Lateral Sclerosis Treatment	Jul 7, 2023	Rapid Review	Completed	RC1487-000
Treatment of Adult Patients With Immune Thrombocytopenia After Failure of First-Line Therapies	Treatment of Adult Patients With Immune Thrombocytopenia After Failure of First…Project Protocol	Jul 6, 2023	Health Technology Assessment	Completed	HT0035-000
Alternative Therapies to Immunoglobulin for Idiopathic Inflammatory Myopathies	Alternative Therapies to Immunoglobulin for Idiopathic Inflammatory Myopathies	Jun 29, 2023	Rapid Review	Completed	RC1484-000
Antimicrobial or Antiseptic Cleansers for Wounds	Antimicrobial or Antiseptic Cleansers for Wounds	Jun 28, 2023	Rapid Review	Completed	RC1488-000
Deep Brain Stimulation Surgery Programs in Canada	Deep Brain Stimulation Surgery Programs in Canada	Jun 13, 2023	Technology Review	Completed	HC0065-000
Alternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases	Alternative Therapies to Immunoglobulin for Autoimmune Blistering Diseases	May 29, 2023	Summary with Critical Appraisal	Completed	RC1483-000
Chloroprocaine for Spinal or Epidural Anesthesia	Chloroprocaine for Spinal or Epidural Anesthesia	May 19, 2023	Rapid Review	Completed	RC1482-000
Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer	Bevacizumab for Recurrent Platinum-Sensitive Ovarian Cancer	May 17, 2023	Rapid Review	Completed	RC1481-000
Overview of HTA Processes for Time-limited Recommendations	Overview of HTA Processes for Time-limited Recommendations	May 16, 2023	Environmental Scan	Completed	ES0377-000
Alternative Therapies to Immunoglobulin for Guillain-Barré Syndrome	Alternative Therapies to Immunoglobulin for Guillain-Barré Syndrome	May 15, 2023	Rapid Review	Completed	RC1480-000
Privately Operated Medical Imaging Facilities Across Canada	Privately Operated Medical Imaging Facilities Across Canada	May 12, 2023	CMII Service	Completed	CM0007-000
Occupational Therapy for Mental Health Conditions and Substance Use Disorders	RC1478 OT and Mental Health.pdf	Apr 27, 2023	Rapid Review	Completed	RC1478-000
Risk of Sexual Transmission of HIV With Antiretroviral Therapy and Variable or Suppressed Viral Load	Risk of Sexual Transmission of HIV With Antiretroviral Therapy and Variable or …	Apr 25, 2023	Technology Review	Completed	HC0050-000
Alternative Therapies to Immunoglobulin for Multifocal Motor Neuropathy	Alternative Therapies to Immunoglobulin for Multifocal Motor Neuropathy	Apr 21, 2023	Rapid Review	Completed	RC1479-000
Considerations of Access and Inclusion in Adolescent Eating Disorder Care: A Custom Rapid Report	Considerations of Access and Inclusion in Adolescent Eating Disorder Care: A Cu…	Apr 20, 2023	Technology Review	Completed	HC0043-000
Formulary Management of Biologics in Plaque Psoriasis	Formulary Management of Biologics in Plaque Psoriasis	Mar 24, 2023	Technology Review	Completed	HD0011-000
Living With Type 2 Diabetes	Living With Type 2 Diabetes	Mar 24, 2023	Technology Review	Completed	HC0045-000
Tocilizumab for Neuromyelitis Optica Spectrum Disorder	Tocilizumab for Neuromyelitis Optica Spectrum Disorder	Mar 24, 2023	Rapid Review	Completed	RC1477-000
Canakinumab for Adult-Onset Still Disease	Canakinumab for Adult-Onset Still Disease	Mar 22, 2023	Rapid Review	Completed	RC1475-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 176 - 200 of 2138

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Large B cell lymphoma	Final Report	Feb 11, 2025	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0064-000
lebrikizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Feb 11, 2025	Reimbursement Review		Complete	SR0819-000
Association Between Opioid Use and the Development of Diverticulitis	Association Between Opioid Use and the Development of Diverticulitis Summary Report Final Project Protocol	Feb 10, 2025	Health Technology Review	Observational Study	Completed	OS0001-000
aflibercept 8mg/0.07mL	Recommendation and Reasons Patient and Clinician Group input Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	SR0813-000
teriflunomide	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Combined Report Supplemental Materials Feedback on Draft Recommendation Patient, Clinician and Industry Input	Feb 10, 2025	Reimbursement Review		Complete	SX0752-000
everolimus	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient, Clinician and Industry Group Input	Feb 10, 2025	Reimbursement Review		Complete	SX0836-000
Mepolizumab	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input Feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	SX0839-000
dimethyl fumarate	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Combined Report Supplemental Materials Feedback on Draft Recommendation Patient, Clinician and Industry Input	Feb 10, 2025	Reimbursement Review		Complete	SX0751-000
blinatumomab	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Combined Report Supplemental Materials Patient, Clinician and Industry Input Feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	PX0367-000
Enzalutamide	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient, Clinician and Industry Group Input Feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	PX0366-000
nivolumab ipilimumab	Recommendation and Reasons Responses to the Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Combined Report Supplemental Materials Patient, Clinician and Industry Input Feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	PX0371-000
panitumumab	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder input	Feb 10, 2025	Reimbursement Review		Complete	PX0333-000
baricitinib	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Feb 10, 2025	Reimbursement Review		Complete	SR0843-000
High Dose Bupropion for Depression	High Dose Bupropion for Depression	Feb 7, 2025	Health Technology Review	Rapid Review	Completed	RC1564-000
abemaciclib	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Feb 7, 2025	Reimbursement Review		Complete	PC0345-000
Colorectal cancer	Final Report	Feb 6, 2025	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0062-000
erdafitinib	Recommendation and Reason Patient and Clinician Group input	Feb 5, 2025	Reimbursement Review		Active	PC0375-000
leuprolide mesylate	Patient and Clinician Group Input	Feb 3, 2025	Reimbursement Review		Active	PC0370-000
Chronic lymphocytic leukemia (CLL)	Final Report	Jan 31, 2025	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0063-000
Health System Readiness for Disease-Modifying Therapies for Alzheimer's Disease	Final Report Summary Report	Jan 30, 2025	Health Technology Review		Active	CM0003-000
durvalumab, olaparib, carboplatin, paclitaxel	Patient and Clinician Group Input	Jan 30, 2025	Reimbursement Review		Withdrawn	PC0366-001
pembrolizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Jan 30, 2025	Reimbursement Review		Complete	PC0356-000
osimertinib	Recommendation and Reason Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Jan 30, 2025	Reimbursement Review		Complete	PC0336-000
Utilization of Drugs in Patients With Major Neurocognitive Disorder		Jan 29, 2025	Health Technology Review	Technology Review	In Progress	HC0099-000
Trends in hydromorphone prescribing in Canada from 2018 to 2024		Jan 29, 2025	Health Technology Review	Technology Review	In Progress	HC0096-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81